Estrogen receptors (ERs) are normally expressed in breast tissues and mediate hormonal functions during development and in female reproductive physiology. In the majority of breast cancers, ERs are involved in regulating tumor cell proliferation and serve as prognostic markers and therapeutic targets in the management of hormonedependent tumors. At the molecular level, ERs function as ligand-dependent transcription factors and activate targetgene expression following hormone stimulation. Recent transcriptomic and whole-genome-binding studies suggest, however, that ligand-activated ERs can also repress the expression of a significant subset of target genes. To characterize the molecular mechanisms of transcriptional repression by ERs, we examined recruitment of nuclear receptor coregulators, histone modifications and RNA polymerase II docking at ER-binding sites and cisregulatory regions adjacent to repressed target genes. Moreover, we utilized gene expression data from patient samples to determine potential roles of repressed target genes in breast cancer biology. Results from these studies indicate that nuclear receptor corepressor recruitment is a key feature of ligand-dependent transcriptional repression by ERs, and some repressed target genes are associated with disease progression and response to endocrine therapy. These findings provide preliminary insights into a novel aspect of the molecular mechanisms of ER functions and their potential roles in hormonal carcinogenesis and breast cancer biology.
Estrogen receptors (ERs) are normally expressed in breast tissues and mediate hormonal functions during development and in female reproductive physiology. In the majority of breast cancers, ERs are involved in regulating tumor cell proliferation and serve as prognostic markers and therapeutic targets in the management of hormonedependent tumors. At the molecular level, ERs function as ligand-dependent transcription factors and activate targetgene expression following hormone stimulation. Recent transcriptomic and whole-genome-binding studies suggest, however, that ligand-activated ERs can also repress the expression of a significant subset of target genes. To characterize the molecular mechanisms of transcriptional repression by ERs, we examined recruitment of nuclear receptor coregulators, histone modifications and RNA polymerase II docking at ER-binding sites and cisregulatory regions adjacent to repressed target genes. Moreover, we utilized gene expression data from patient samples to determine potential roles of repressed target genes in breast cancer biology. Results from these studies indicate that nuclear receptor corepressor recruitment is a key feature of ligand-dependent transcriptional repression by ERs, and some repressed target genes are associated with disease progression and response to endocrine therapy. These findings provide preliminary insights into a novel aspect of the molecular mechanisms of ER functions and their potential roles in hormonal carcinogenesis and breast cancer biology. Oncogene (2011 Oncogene ( ) 30, 1608 Oncogene ( -1614 doi:10.1038 /onc.2010 published online 22 November 2010 Keywords: estrogen receptor; transcriptional regulation; hormonal carcinogenesis; coregulators Estrogens and their cellular receptors play key roles during development and in reproductive physiology and endocrine-related diseases, including breast cancers (Gruber et al., 2002; Yager and Davidson, 2006) . Two estrogen receptor (ER) subtypes, ERa and ERb, have been identified and exhibit differential target tissue distribution and functions. In the majority of breast cancers, ERa is expressed in tumor cells and is involved in promoting tumor cell proliferation and invasiveness (Ali and Coombes, 2000) . The role of ERb in breast cancer biology remains to be determined, although some findings suggest that it may attenuate ERa functions (Lindberg et al., 2003; Cappelletti et al., 2004; Lin et al., 2007a) . ER status is an important prognostic marker in breast cancer management and a determinant for treatment with selective estrogen receptor modulators. Treatment with selective estrogen receptor modulators has also been shown to be effective in reducing the risk of breast cancer (Fisher et al., 1998 (Fisher et al., , 2005 Vogel et al., 2006) . However, inhibiting estrogen or ER functions elicits menopausal symptoms in premenopausal women and negates other beneficial effects, such as bone maintenance and cardiovascular protection. Long-term application of endocrine therapy may result in drug resistance and hormone-independence in tumor cells (Bookman, 2005) . Overcoming these challenges will necessitate a more complete understanding of the molecular mechanisms of ER function.
ER is a nuclear receptor and affects target-gene expression directly as a ligand-dependent transcription factor (Nilsson and Gustafsson, 2002) . Upon activation, ER upregulates target-gene expression by binding cis-regulatory estrogen response elements (EREs) and nucleating coregulator complexes that modify histones and render the DNA accessible to the transcriptional machinery (Shang et al., 2000; Metivier et al., 2003) . ER coregulators include those which enhance transcriptional activity by affecting nucleosome spatial orientatioin or by modifying histones through acetylation (SRC1, CBP/p300, p/CAF and p/CIP/AIB1) and methylation (CARM1 and PRMT1) (Halachmi et al., 1994; Onate et al., 1995; Lin et al., 1996; Ogryzko et al., 1996; Wang et al., 1996 Wang et al., , 2001 Anzick et al., 1997; Chen et al., 1999; Phelan et al., 1999; Sterner and Berger, 2000) . Coregulators, such as NCoR, SMRT, NRIP1, LCoR and REA, function as nuclear receptor corepressors, and have been shown to bind ER following selective estrogen receptor modulator treatments, but their roles in normal ER transcriptional activity are not known (Chen and Evans, 1995; Treuter et al., 1998; Hu and Lazar, 1999; Montano et al., 1999; Webb et al., 2000; Fernandes et al., 2003) .Research into ER transcriptional regulatory mechanisms has focused mainly on genes, such as vitellogenin and pS2/TFF1, whose expression levels are upregulated following estrogen stimulation. Consequently, most of the current models of transcriptional regulation by ER are based on molecular and biochemical studies of the EREs adjacent to these upregulated target genes. Microarray analyses of transcriptomic alterations following estrogen treatments suggest, however, that a large number of responsive genes are transcriptionally repressed (Frasor et al., 2003; Lin et al., 2004) . Whole-genome cartography of ER-binding sites by chromatin immunoprecipitation (ChIP) coupled with either microarray (ChIP-chip) or high-throughput sequencing (ChIP-seq) technologies has mapped ER to cis-regulatory regions of both activated and repressed target genes (Carroll et al., 2005 (Carroll et al., , 2006 Lin et al., 2007b) . Mechanisms of liganddependent transcriptional repression of ER direct target genes have not been studied in detail. Carroll et al. propose that transcriptional repression by ER occurs at late time points following estrogen exposure and may involve potential interactions with AP-1 factors (Carroll et al., 2006) . They also demonstrated that the corepressor NRIP1 is involved in the late repression of target genes adjacent to AP-1-binding site motif containing ER-binding sites. They did not address experimentally, however, the observed early repression events and mechanisms, the role of AP-1 factors, the general effects of NRIP1 in transcriptional repression by ER and the involvement of other corepressors. A report by Stossi et al. showed that the nuclear receptor corepressor NCoR is recruited to the promoter region of the cyclin G2 gene, previously shown to be repressed by ER (Frasor et al., 2003; Lin et al., 2004) , at two hours following estrogen treatment, a much earlier time point than the repression events examined by Carroll et al. (Stossi et al., 2006) , and they also demonstrated the involvement of p300 and CtBP1 in a recent study (Stossi et al., 2009) . Much of the mechanisms of transcriptional repression by ER still remain to be elucidated.
Based on known general and ER-specific transcriptional regulatory mechanisms, we hypothesize that, in cases of transcriptional repression, ligand-activated ER interacts with specific factors and binding site sequence motifs adjacent to repressed target genes, and these supplemented with 5% charcoal-dextran-stripped fetal bovine serum (HyClone, Logan, UT, USA) for 72 h. Following estrogen deprivation, cells were either incubated with 10 nM estradiol (E2; Sigma-Aldrich, St Louis, MO, USA) or mock treated with the ethanol carrier for E2. Treatments ranged from 45 min and 2, 12 and 24 h. Chromatin was cross-linked with 1.5% formaldehyde in phosphate buffered saline solution for 15 min at room temperature, followed by a series of nucleus/chromatin preparation (NCP) buffer washings. Cells were washed sequentially with 1 ml of phosphate buffered saline, NCP I (10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES, pH ¼ 6.5, 0.25% Triton X-100) and NCP II (1 mM EDTA, 0.5 mM EGTA, 10 mM HEPES, 200 mM NaCl). Following NCP buffer washings, isolated nuclei were resuspended in lysis buffer (10 mM EDTA, 20 mM Tris-HCl, pH ¼ 8.1, 0.5% Empigen BB (Sigma-Aldrich, St Louis, MO, USA), 1% SDS) and incubated at room temperature for 10 min. Nuclear extracts were then sonicated to solubilize protein-DNA complexes and clarified by centrifugation. Aliquots of extracts were retained as input controls for subsequent analysis. Immunoprecipitation buffer (2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH ¼ 8.1, 1% Triton X-100, protease inhibitors) and anti-ERa antibodies (HC-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were added to the nuclear extracts and incubated overnight at 4 1C. Following incubation, 50% Protein A-sepharose bead (Invitrogen) slurry in beads buffer (10 mM Tris-HCl pH ¼ 8.1, 1 mM EDTA) was added and immunoprecipitation continued for 3 additional h. Beads were then washed sequentially with wash buffer (WB) I (2 mM EDTA, 20 mM Tris-HCl, pH ¼ 8.1, 0.1% SDS, 1% Triton X-100, 150 mM NaCl), WB II (same as WB I except 500 mM NaCl), WB III (10 mM Tris-HCl, pH ¼ 8.1, 1 mM EDTA, 250 mM LiCl, 1% Deoxycholate, 1% NP-40) and WB IV (10 mM Tris-HCl, pH ¼ 8.1, 1 mM EDTA) at 4 1C. Protein-DNA complexes were extracted three times with extraction buffer (1% SDS, 0.1 M NaHCO3) and de-cross-linked at 65 1C overnight. ChIP and input control DNA were isolated using the QIAquick PCR purification kit (Qiagen, Valencia, CA, USA). Specific PCR primers targeting the sites adjacent to two repressed target genes (PSCA and SLC35A1) were used to determine binding of ER at 45 min following estrogen treatment (PSCA ERE, forward primer, 5 0 -CACAGGGATGTGTGTTCCAG-3 0 , reverse primer, 5 0 -TCCCTGGAGATCCTGTCTTC-3 0 ; SLC35A1 ERE, forward primer, 5 0 -TTTGCAACCACAAAGGTGAC-3 0 , reverse primer, 5 0 -GCCTCCCTCCCTATTCTGTC-3 0 ). The previously characterized GREB1 ERE (Lin et al., 2004) was included as a positive control for ER binding (GREB1 ERE, forward primer, 5 0 -AGCAGTGAAAAAAGTGTGGCAACTGGG-3 0 , reverse primer, 5 0 -CGACCCACAGAAATGAAAAGGCAGCAAACT-3 0 ). Control ChIPs using anti-hemagglutinin (Santa Cruz Biotechnology) antibodies showed no non-specific binding of the sites following hormone treatment. (b) Quantitative PCR was performed on a Roche LightCycler 480 system using the SYBR Green master mix (Roche, Indianapolis, IN, USA) to determine the extent of ER recruitment following 45 min and 2, 12 and 24 h of estrogen treatment. Results were normalized to input DNA data and presented as relative average fold-change between treated and untreated samples for three biological replicates. Error bars represent s.e.m. fold changes.
Differential recruitment of nuclear receptor coregulators KW Merrell et al molecular interactions confer a repressive receptor conformation. The repressive conformation then promotes recruitment of corepressors, expulsion of co-activators, alteration of histone modifications, and disruption of RNA polymerase II (Pol II) docking. Furthermore, we posit that genes involved in the mechanisms of transcriptional repression by ER and repressed target genes constitute a significant and little understood aspect of ER biology, and are likely associated with disease parameters and outcomes in breast cancer patients.
To determine the recruitment of the co-activators and corepressors to repression-associated ER-binding sites, we examined the overlap between our previously published mapping results (Lin et al., 2007b) and available microarray data (Finlin et al., 2001; Soulez and Parker, 2001; Frasor et al., 2003; Lin et al., 2004) , and selected ER-binding sites adjacent to two repressed target genes (PSCA and SLC35A1) for validation and characterization. ER binding to these sites following estrogen treatment was first validated by conventional ChIP. PCR of the ChIP samples confirmed ER binding at 45 min following hormone treatment as compared with the mock-treated controls (Figure 1a) . ER binding to the previously characterized ERE adjacent to the GREB1 gene was included as a positive control. There is no binding of these sites in the immunoprecipitation controls using the irrelevant anti-hemagglutinin antibodies, and there were either negligible or no estrogendependent binding in control exonic regions of the repressed target genes (data not shown). ER binding to these sites was then further characterized by ChIP and quantitative PCR at 45 min and 2, 12 and 24 h following hormone treatment (Figure 1b) . ER recruitment to these (Metivier et al., 2003) . Following the initial anti-ERa ChIP, up to the final wash step, ER-chromatin complexes were extracted by the addition of 10 mM dithiothreitol (DTT) and incubated for 20 min at 37 1C. Supernatants from the extraction procedure were pooled together and diluted with re-ChIP buffer (20 mM Tris-HCl, pH ¼ 8.1, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100), and additional IP buffer and 1 mg of antibodies against the selected coregulator were added, and re-ChIP mixtures were incubated overnight at 4 1C. Isolation of specific coregulator complexes and purification of associated DNA was carried out as described for standard ChIP experiments. Coregulator binding was determined by quantitative PCR as previously described. Recruitment to the extensively characterized pS2 ERE (Shang et al., 2000; Metivier et al., 2003) was included as a control (pS2 ERE, forward primer, 5 0 -CCATGTTGGCCAGGCTAGTC-3 0 , reverse primer, 5 0 -ACAACAGTGGCTCACGGGCT-3 0 ). Control PCR experiments were also carried out using primers designed against exonic regions of repressed target genes (PSCA exon 3, forward primer, 5 0 -TGGCCCAGCATTCTCCACCCTT-3 0 , reverse primer, 5 0 -GGGACACCACGGACCAGACCT-3 0 ; SLC35A1 exon 4, forward primer, 5 0 -GACCTACCAGTTGAAGATTCCG-3 0 , reverse primer, 5 0 -AAGCGTAACTCCAGCACACA-3 0 ), and detected either no binding or no differences between mock-and E2-treated ChIP and re-ChIP samples (data not shown). Co-activator recruitment re-ChIP studies were performed using antibodies against SRC1 (Santa Cruz Biotechnology) and p/CIP (Santa Cruz Biotechnology). (b) Specific antibodies against NCoR (Santa Cruz Biotechnology), SMRT (Santa Cruz Biotechnology) and NRIP1 (Abcam, Cambridge, MA, USA) were used for the corepressor studies. Statistically significant (Po0.05; two-tailed Student's t-test) differences between repressed the target gene sites and the activated control pS2 ERE are denoted by asterisks for co-activator and corepressor studies. sites started to diminish at 2 h following hormone treatment, and ER binding at 12 and 24 h were comparable with the mock-treated controls. Subsequent analyses of coregulator recruitment and changes in the chromatin structure were thus limited to the two earlier time points.
Following the validation and characterization of the selected ER-binding sites, we performed 're-ChIP' experiments to determine the binding of the co-activator proteins to the ER complex bound to the sites. Briefly, ChIP was carried out using anti-ER antibodies first, followed by a second ChIP with antibodies against either SRC1 or p/CIP. MCF-7 cells were treated with estrogen for 45 min and 2 h before the assays. The ERE in the promoter region of the previously characterized pS2 gene was included as a positive control. Both SRC-1 and p/CIP are recruited to the pS2 ERE following hormone treatment (Figure 2a ). This is consistent with previously published results (Shang et al., 2000; Metivier et al., 2003) . For the repressed target gene sites, SRC-1 is expelled from the ER complex at both sites examined after 2 h of hormone treatment (Figure 2a) , whereas, in contrast, p/CIP is expelled from one of the two repression-associated sites following estrogen treatment (Figure 2a) . Differences in the co-activator recruitment between the repressed target gene sites and the pS2 ERE were statistically significant (Po0.05; Student's t-test), with the exception of the PSCA site at 45 min. Therefore, our theory regarding the expulsion of the coactivators appears partially correct, and the actual model may differ depending on the binding site and co-activator examined.
To test whether the corepressors are recruited to the repression-associated ER-binding sites, we performed re-ChIP experiments as described for the co-activators. Specifically, we examined the recruitment of NCoR, NRIP1 and SMRT ( Figure 2b ). As we had posited, all three corepressors, perhaps components of the same corepressor complex, are recruited to the ER bound to both of the repressed target gene sites following 45 min and 2 h of estrogen treatment, with the exception of NRIP1 recruitment to the PSCA ER-binding sites at 2 h after treatment (Figure 2b ). Increases in NCoR and SMRT recruitment to the repressed target gene sites, as compared with the pS2 ERE, are statistically significant (Po0.05; Student's t-test) at both time points, whereas differences in NRIP1 binding are significant or nearly significant (Po0.1) at 2 h, although the repressed target gene sites appeared to recruit NRIP1 at 45 min. In all instances, the corepressors are present at the pS2 ERE in the absence of estrogen and are expelled following hormone treatment, suggesting a mechanism for suppressing basal transcriptional activity for this upregulated ER target gene. These findings suggest that recruitment of the nuclear receptor corepressors is a common mechanism for transcriptional repression by ER.
Nuclear receptor corepressors NCoR, NRIP1 and SMRT are known to interact with histone deacetylases and block transcriptional activity by altering interactions between DNA and histones (Wei et al., 2000; Guenther et al., 2001) . As these corepressors are recruited to the ER complex adjacent to repressed target genes, we performed ChIP experiments to determine the effect of their recruitment on the histone acetylation status in the promoter regions of these genes and the impact on Pol II docking. MCF-7 cells were treated with estrogen for 45 min or 2 h, and ChIPs were carried out using specific antibodies against acetylated histones H3 (K14) and H4 (K16), both associated with transcriptionally active promoters (Hebbes et al., 1988) , or Pol II.
For both of the repressed ER target gene promoters tested, histones H3 and H4 acetylation decreased at both 45 min and 2 h following hormone treatment (Figure 3) . Transcriptional repression by ER is associated with histone deacetylation and reduced RNA Pol II docking in the promoter regions of target genes. Histone acetylation and Pol II binding in the promoter regions of PSCA and SLC35A1 genes were determined by ChIP assays using specific antibodies against acetylated histones H3 and H4 (Upstate Biotech/Millipore, Billerica, MA, USA) and Pol II (Santa Cruz Biotechnology), and quantitative PCR as described for the ER binding studies (PSCA promoter, forward primer, 5 0 -AGGGAGAGGGAGGTGCAGGT-3 0 , reverse primer, 5 0 -CAAATGGGGAGAGGCTGGAC-3 0 ; SLC35A1 promoter, forward primer, 5 0 -ATCCGCGTTCTCCCCATTTT-3 0 , reverse primer, 5 0 -ACCGCCCCTTGTGGTCAT-3 0 ; pS2 promoter, primers same as pS2 ERE) was carried out. Statistically significant (Po0.05; two-tailed Student's t-test) differences between the repressed target gene promoters and the activated control pS2 promoter are denoted by asterisks.
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In contrast, histone acetylation increased in the promoter region of the pS2 gene, consistent with an increase in its expression following estrogen treatment. Decreases in the histone H4 acetylation were statistically significant (Po0.05; Student's t-test) at 2 h for both repressed target genes as compared with pS2, and differences at 45 min and also in histone H3 acetylation were nearly significant (Po0.1). In line with the observed changes in histone acetylation status, Pol II is recruited to the pS2 promoter but not the promoters of the two repressed target genes (Figure 3 ) where it's binding was actually decreased following estrogen treatment. Pol II recruitment to the PSCA promoter was significantly different at 45 min, whereas recruitments at 2 h to the SLC35A1 promoter were nearly significant and clearly showed similar trends.
In these studies, we examined potential mechanisms of transcriptional repression by ER involving the nuclear receptor co-activators and corepressors. The most consistent trend is the recruitment of the corepressors to the repressed target gene ER-binding sites, although NRIP1, which is reported to have both the corepressor and co-activator activity (Cavailles et al., 1995; Treuter et al., 1998) , appeared to be present in the complex at the earlier time point and absent in the latter for the PSCA ER-binding site. We did not measure NRIP1 recruitment to these sites at 12 h following (Sjogren et al., 1996) . The follow-up RNA expression profiling study was approved by the ethical committee at the Karolinska Institute, Stockholm, Sweden. Affymetrix (Santa Clara, CA, USA) oligonucleotide microarrays (U133A&B) were used to determine gene expression profiles in breast tumor samples. After exclusions based on RNA integrity and array quality control, expression profiles of 260 tumors were deemed suitable for further analysis. To assess the role of repressed ER target genes in breast tumor biology, we selected the 69 ER-positive tumors from patients who underwent adjuvant tamoxifen therapy. Clinicopathological characteristics were derived from the patient records and routine clinical measurements at the time of diagnosis. Histopathological reexamination and grading according to Elston-Ellis were performed by an experienced breast cancer pathologist without previous knowledge of the selected therapies and outcomes as described previously (Miller et al., 2005) . Gene expression data are presented as mean-centered log2-transformed normalized intensity for the probe set. Distances between expression profiles were calculated based on Pearson correlation, and the average-linkage method from the Eisen Cluster program (http://rana.lbl.gov/EisenSoftware.htm) was used to cluster patient samples. Expression profiles of four recurrence-associated ER-repressed target genes (MME, COPL, CYP1A1 and Dicer 1) were used to cluster patients. (b) Kaplan-Meier plot of 10-year-censored disease-free survival curves for patients clustered by expression profiles of ER-repressed target gene is shown with the associated P-value from likelihood-ratio analysis. (c) Nuclear receptor co-activator recruitment to the MME ER-binding site was determined by re-ChIP experiments as described previously (MME ERE, forward primer, 5 0 -GCCCCTTCCAGCTTCTCTAT-3 0 , reverse primer, 5 0 -GCAGGAAGGGAATGAGCA-3 0 ). Control PCR experiments were carried out using primers designed against exon 23 of the MME gene (MME exon 23, forward primer, 5 0 -TCAGAAGCCTTTCACTGCCGCA-3 0 , reverse primer, 5 0 -GCAAGTCTAGCCAAGGGCTGCA-3 0 ) and detected either no binding or no differences between mock-and E2-treated ChIP and re-ChIP samples (data not shown). Statistically significant (Po0.05; two-tailed Student's t-test) differences between the MME ER-binding site and the activated control pS2 ERE are denoted by asterisks. (d) Corepressor recruitment was similarly studied by re-ChIP. (e) Histone acetylation and RNA Pol II binding in the promoter region of the MME gene were examined by conventional ChIP and quantitative PCR (MME promoter, forward primer, 5 0 -CCCCGAAGCTAAGCAATTC-3 0 , reverse primer, 5 0 -AAGGTTTCCGCTAGGTCTCC-3 0 ). Statistically significant (Po0.05; twotailed Student's t-test) differences between the MME promoter region and the activated control pS2 promoter are denoted by asterisks.
Differential recruitment of nuclear receptor coregulators KW Merrell et al estrogen treatment, as was reported by Carroll et al. for the repressed target genes they examined, as in our studies, ER does not appear to be bound to our sites after 12 h of hormone exposure (Figure 1b) . These disparate findings suggest that a more detailed analysis, including sites from both studies, is warranted to resolve the apparent differences. In contrast to the corepressors, the co-activator recruitment to the repression-associated ER-binding sites was much more varied. SRC1 and p/CIP were recruited to some of the binding sites and expelled from others. The recruitment and expulsion of the co-activators appeared to be both site-and time dependent. Even when the co-activators were present in the ER complex, however, the reduction in histone acetylation in the promoter regions of repressed target genes suggests that the histone deacetylases associated with the corepressors were exerting a greater influence on the chromatin structure and transcriptional activity. What is unclear is how ER is able to recruit corepressors to the repression-associated cis-regulatory sites as opposed to the recruitment of co-activators in the canonical model of transcriptional activation of the pS2 gene following estrogen treatment. No differences in the ERE motifs in repression-associated ER-binding sites were detected when compared with those associated with transcriptional activation by ER (data not shown).
There is a lower frequency of EREs in repressed sites and an enrichment of ER-binding sites in the promoter regions of activated target genes; ER-binding sites adjacent to repressed target genes are more dispersed and does not appear to be localized to a specific region relative to the target gene (Lin et al., 2007b) . Recent analysis has also revealed the enrichment of a number of transcription factor-binding site motifs within the ERbinding regions of the repressed target genes, and initial studies suggest the involvement of the transcription factor RUNX1 in the repression of SLC35A1 by ER (unpublished data). Another import question regarding mechanisms of transcriptional repression by ER is how these mechanisms are affected by different ER agonists and antagonists. Preliminary results show that tamoxifen functions as an agonist on repressed target genes, whereas raloxifene exhibits antagonistic activity; some phytoestrogens also function as agonists on repressed ER target genes (unpublished data). Given the involvement of estrogens and ER in breast cancer, we further posit that these mechanisms and repressed target genes likely play key roles in breast cancer biology. To determine their potential involvement in disease parameters and outcome, we analyzed the expression profiles of all of the putative repressed target genes identified in mapping and microarray studies (Finlin et al., 2001; Soulez and Parker, 2001; Frasor et al., 2003; Lin et al., 2004 Lin et al., , 2007b in a previously published microarray gene expression dataset of 69 ER-positive breast cancer patient samples (Lin et al., 2007a) . All of the patients received selective estrogen receptor modulator (tamoxifen) treatment following surgery. When patients were grouped into those with recurrent disease and those without, we identified four repressed target genes, which were significantly (Po0.05; Wilcoxon rank-sum test) differentially expressed between the two patient groups. Hierarchical clustering of patients using the expression profiles of these four genes revealed three major clusters (Figure 4a) . Kaplan-Meier analysis of disease-free survival ( Figure 4b ) indicated a significant (likelihood ratio test, P ¼ 0.00417) association of one of the clusters with poor prognosis. We then confirmed ER binding to the site adjacent to one of these genes, membrane metallo-endopeptidase, by ChIP (data not shown) and observed similar patterns of the co-activator expulsion, corepressor recruitment, histone deacetylation and blockage of Pol II docking in the promoter region (Figures 4c-e) as the two repressed target genes (PSCA and SLC35A1) selected for the mechanistic studies. These results suggest that some of the repressed target genes are associated with disease progression and response to endocrine therapy, and these genes and the mechanisms of transcriptional repression by ER warrant further study and evaluation as potential prognostic markers and therapeutic targets in the treatment of ERpositive breast cancers.
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